Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring
Phase 2
Completed
- Conditions
- Acne Scarring of the Face
- Interventions
- Biological: Autologous Human Fibroblasts (azficel-T)Biological: Placebo
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 122
- Registration Number
- NCT00642642
- Locations
- ๐บ๐ธ
The Laser Institute for Dermatology, Santa Monica, California, United States
๐บ๐ธMaryland Laser, Skin and Vein Institute, Hunt Valley, Maryland, United States
๐บ๐ธTherapeutics Clinical Research, San Diego, California, United States
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
Phase 2
Withdrawn
- Conditions
- Restrictive Burn Scars of Joint Area
- Interventions
- Biological: Autologous Human Fibroblasts (Isolagen TherapyTM)Biological: Placebo
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Registration Number
- NCT00620737
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธUniversity of Texas Medical Branch- Galveston, Galveston, Texas, United States
๐บ๐ธNassau County Medical Center, East Meadow, New York, United States